[1] Mitchison DA.The action of antituberculosis drugs in short-course chemotherapy. Tubercle.1985,66(3):219-225.
[2] Mitchison DA. Mechanisms of the action of drugs in the short-course chemotherapy.Bull Int Union Tuberc.1985,60(1-2):36-40.
[3] World Health Organization.Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. Geneva, World Health Organization, 2008(WHO/HTM/TB/2008.402).
[4] Global Alliance for TB Drug Development.Handbook of anti-tuberculosis agents.Tuberculosis,2008,88:85-170. PMID: 18486036
[5] Tomioka H, Namba K. Development of antituberculous drugs: current status and future prospects,Kekkaku. 2006,81(12):753-74.
[6] Senol G,Erbaycu A,Ozsoz A.Incidence of cross resistance between rifampicin and rifabutin in Mycobacterium tuberculosis strains in Izmir, Turkey.J Chemother,2005,17:380-384.
[7] Lu PL,Peng CF,Hwang JJ,et al.Activity of twelve second-line antimicrobial agents against Mycobacterium tuberculosis in Taiwan.J Chemother,2008,20(2):202-207.PMID: 18467246
[8] Moadebi S,Harder CK,Fitzgerald MJ,et al.Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs, 2007, 67(14):2077-2099. PMID: 17883288
[9] Agrawal D, Udwadia ZF, Rodriguez C, et al.Increasing incidence of fluoroquinolone-resistant Mycobacterium tuberculosis in Mumbai, India. Int J Tuberc Lung Dis, 2009,1(1):79-83. PMID: 19105883
[10] Prammananan T, Chaiprasert A, Leechawengwongs M.In vitro activity of linezolid against multidrug-resistant tuberculosis(MDR-TB) and extensively drug-resistant (XDR)-TB isolates.Int J Antimicrob Agents,2009,33(1):190-191.
[11] Nam HS,Koh WJ, Kwon OJ. Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis.Int J Antimicrob Agents,2009,33(1):92-93.
[12] Alcaide F,Calatayud L,Santin M,et al. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii.Antimicrobm Agents Chemother,2004,48:4562-4565.
[13] Falzari K,Zhu ZH,Pan DH,et al.In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis. Antimicrob Agents Chemother,2005,49:1447-1454.
[14] Katiyar SK,Bihari S,Prakash S,et al.A randomized controlled trial of high-dose isoniazid adjuvant therapy for multidrug-reisistant tuberculosis.Int J Tuberc Lung Dis, 2008,12(2):139-145. PMID: 18230245
[15] Aggarwal D, Mohapatra PR,Janmeja AK.Treatment of extensively drug-resistant tuberculosis.Lancet,2009,373:26-27.
|